Incorporating New Technologies through Open Innovation
First written in FY2018. 1 of 3 entries say "Restated". Latest entry: FY2025.
2 other companies' latest entry also says "Advanced".
- FY2025AdvancedAnnual report
「In April 2025, the Company opened a new office, the “Boston Open Innovation Office,” in the Boston area of Massachusetts, US, a global hub of the life sciences ecosystem. The office is operated by the Company’s US subsidiary KISSEI AMERICA, INC., headquartered in Fort Lee, New Jersey. From this base, the Company is enhancing access to advanced research technologies, promoting open innovation, and strengthening its platform for the creation of innovative pharmaceuticals.」
The Company opened an open innovation hub in Boston, giving concrete form to access to advanced research technologies and the adoption of external technologies. - FY2019RestatedAnnual report
「The Company will further strengthen its competitive advantages, deepen its expertise, and adopt new technologies through open innovation to build a drug discovery research platform that continuously generates new drug candidates.」
The Company has reaffirmed the adoption of new technologies through deeper expertise and open innovation as a means of building its drug discovery research platform. - FY2018First statedAnnual report
「The Company will further strengthen its competitive advantages, deepen its expertise, and adopt new technologies through open innovation to build a drug discovery research platform that continuously generates new drug candidates.」
For the first time, the Company explicitly identified as an issue to be addressed measures to adopt new technologies by deepening its expertise and pursuing open innovation, thereby supporting the continuous generation of new drug candidates.